SLRN
Acelyrin
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 3
stock price surged significantly
MACD Golden Cross
Price Hits New Low
Price Hits 52-week low
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SLRN
Acelyrin, Inc
A late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines
4149 Liberty Canyon Road, Agoura Hills, California 91301
--
Acelyrin, Inc was incorporated in Delaware on July 27, 2020. Acelyrin, Inc is a late-stage biopharmaceutical company focused on identifying, acquiring and accelerating the development and commercialization of transformative drugs. Since its inception, the Company has devoted almost all its resources to organizing the Company, recruiting personnel, business planning, acquiring and developing its product candidates, conducting research and development, manufacturing activities to support its product development efforts, building and protecting its intellectual property portfolio, raising funds and providing General And Administrative support for these activities.
Company Financials
EPS
SLRN has released its 2024 Q3 earnings. EPS was reported at -0.49, versus the expected -0.80, beating expectations. The chart below visualizes how SLRN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
